Angelo Amabile, PhD
About Me
Dr. Angelo Amabile is a medical biotechnologist with a strong expertise in gene therapy and genetic engineering. His training began with a PhD in Molecular Medicine at San-Raffaele Telethon Institute for Gene Therapy (SR-TIGET) in Milan, a world leader Institute in the field of lentiviral-vector mediated gene therapy. His work established a new set of DNA editing tools, mainly based on CRISPR/Cas9, for genetic and epigenetic editing of mammalian cells. He subsequently joined Mount Sinai for his postdoctoral studies where he focused on RNA and Lipid Nanoparticles (LNP) technology. During his time at Sinai, Dr. Amabile developed a new technology for targeted delivery of LNPs for cell specific gene and cancer immunotherapy.
Dr. Amabile is Director of the NanoCore Facilty and a member of Icahn Genomics Institute.
Language
English
Position
ASSISTANT PROFESSOR | Immunology & Immunotherapy
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Amabile has not yet completed reporting of industry relationships or has no industry relationships to report.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.